This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aratana To Participate In Leerink Swann's November Management Access Days









KANSAS CITY, Kan. and NEW YORK, Nov. 12, 2012 /PRNewswire/ --  Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced that it will participate in Leerink Swann's November Management Access Days, taking place November 19 - 20, 2012, at Leerink Swann's headquarters in Boston, Massachusetts. 

On November 19, 2012, Steven St. Peter, M.D., President and Chief Executive Officer of Aratana, will host one-on-one meetings with investors.  He will be joined by Louise Mawhinney, CPA, Chief Financial Officer, and Linda Rhodes, V.M.D., Ph.D., Chief Scientific Officer of Aratana Therapeutics. 

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

For Media & Investors: Jason Rando / Joshua Drumm, Ph.D.Tiberend Strategic Advisors, Inc.(212) 827-0020 jrando@tiberend.com jdrumm@tiberend.com

 

SOURCE Aratana Therapeutics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs